新元资本旗下基金向Sanofi出售Kymab项目 涉资最少11亿美元
新元资本宣布,新元一期基金与Sanofi(SNY.US)於本周一(11日)达成协议,出售其於临床阶段生物制药公司Kymab之权益予赛诺菲。作为代价,赛诺菲将支付11亿美元首期付款、及在达成某些里程碑後支付额外最多3.5亿美元,予退出Kymab的投资者。上述交易预计於2021年上半年完成。同时,新元资本今天亦宣布完成其新元二期基金之首轮募集。
Kymab为新元一期基金最大的投资项目,基金与海普瑞(09989.HK)共同领投了Kymab於2016年11月完成的C轮优先股融资,新元一期基金其後在2019年和2020年先後对Kymab进行了後续投资。
Kymab是一家成立於2010年的临床阶段的英国生物制药公司,透过其专有的集成平台IntelliSelect,开发全人源化单克隆抗体治疗剂,并专注於免疫介导的疾病和免疫肿瘤学。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.